Second Sight Medical Products (EYES) Earning Somewhat Positive Media Coverage, Analysis Finds

News coverage about Second Sight Medical Products (NASDAQ:EYES) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Second Sight Medical Products earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave media coverage about the medical device company an impact score of 44.2552182718572 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

Shares of Second Sight Medical Products (NASDAQ EYES) opened at $1.89 on Monday. The stock has a market capitalization of $105.69, a price-to-earnings ratio of -2.82 and a beta of 3.67. Second Sight Medical Products has a 1-year low of $0.90 and a 1-year high of $2.83.

Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings data on Thursday, November 2nd. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. The firm had revenue of $1.61 million for the quarter, compared to the consensus estimate of $1.54 million. Second Sight Medical Products had a negative return on equity of 184.87% and a negative net margin of 565.12%. analysts expect that Second Sight Medical Products will post -0.55 earnings per share for the current year.

Several equities analysts have recently commented on EYES shares. Zacks Investment Research lowered Second Sight Medical Products from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. HC Wainwright set a $5.00 price target on Second Sight Medical Products and gave the company a “buy” rating in a research note on Tuesday, October 17th.

COPYRIGHT VIOLATION WARNING: “Second Sight Medical Products (EYES) Earning Somewhat Positive Media Coverage, Analysis Finds” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.com-unik.info/2017/12/25/second-sight-medical-products-eyes-earning-somewhat-positive-media-coverage-analysis-finds.html.

About Second Sight Medical Products

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit